Citations (63)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (11)
Stephen M. Farmer & Claudia D. Andl. (2021) Computational modeling of transforming growth factor β and activin a receptor complex formation in the context of promiscuous signaling regulation. Journal of Biomolecular Structure and Dynamics 39:14, pages 5166-5181.
Read now
Read now
Rita Greco, Hongjing Qu, Hui Qu, Joachim Theilhaber, Gary Shapiro, Richard Gregory, Christopher Winter, Natalia Malkova, Frank Sun, Julie Jaworski, Annie Best, Lily Pao, Andrew Hebert, Mikhail Levit, Alexei Protopopov, Jack Pollard, Keith Bahjat, Dmitri Wiederschain & Sharad Sharma. (2020) Pan-TGFβ inhibition by SAR439459 relieves immunosuppression and improves antitumor efficacy of PD-1 blockade. OncoImmunology 9:1.
Read now
Read now
Alice Guazzelli, Parisa Meysami, Emyr Bakker, Ezio Bonanni, Constantinos Demonacos, Marija Krstic-Demonacos & Luciano Mutti. (2019) What can independent research for mesothelioma achieve to treat this orphan disease?. Expert Opinion on Investigational Drugs 28:8, pages 719-732.
Read now
Read now
Emyr Bakker, Alice Guazzelli, Firozeh Ashtiani, Constantinos Demonacos, Marija Krstic-Demonacos & Luciano Mutti. (2017) Immunotherapy advances for mesothelioma treatment. Expert Review of Anticancer Therapy 17:9, pages 799-814.
Read now
Read now
Sulsal Haque & John C. Morris. (2017) Transforming growth factor-β: A therapeutic target for cancer. Human Vaccines & Immunotherapeutics 13:8, pages 1741-1750.
Read now
Read now
Alice Guazzelli, Emyr Bakker, Kun Tian, Constantinos Demonacos, Marija Krstic-Demonacos & Luciano Mutti. (2017) Promising investigational drug candidates in phase I and phase II clinical trials for mesothelioma. Expert Opinion on Investigational Drugs 26:8, pages 933-944.
Read now
Read now
Marla Karine Amarante, Carlos Eduardo Coral de Oliveira, Carolina Batista Ariza, Alberto Yoichi Sakaguchi, Cintya Mayumi Ishibashi & Maria Angelica Ehara Watanabe. (2017) The predictive value of transforming growth factor-β in Wilms tumor immunopathogenesis. International Reviews of Immunology 36:4, pages 233-239.
Read now
Read now
Emyr Bakker, Alice Guazzelli, Marija Krstic-Demonacos, Michael Lisanti, Federica Sotgia & Luciano Mutti. (2017) Current and prospective pharmacotherapies for the treatment of pleural mesothelioma. Expert Opinion on Orphan Drugs 5:6, pages 455-465.
Read now
Read now
Daniel Bedinger, Llewelyn Lao, Shireen Khan, Steve Lee, Toshihiko Takeuchi & Amer M. Mirza. (2016) Development and characterization of human monoclonal antibodies that neutralize multiple TGFβ isoforms. mAbs 8:2, pages 389-404.
Read now
Read now
Angela Bononi, Andrea Napolitano, Harvey I Pass, Haining Yang & Michele Carbone. (2015) Latest developments in our understanding of the pathogenesis of mesothelioma and the design of targeted therapies. Expert Review of Respiratory Medicine 9:5, pages 633-654.
Read now
Read now
Sabina Antonela Antoniu, Gabriel Dimofte & Didona Ungureanu. (2014) Immune therapies for malignant mesothelioma. Expert Review of Anticancer Therapy 14:8, pages 965-973.
Read now
Read now
Articles from other publishers (52)
Galaxia M. Rodriguez, Edward Yakubovich & Barbara C. Vanderhyden. (2023) Unveiling the Immunogenicity of Ovarian Tumors as the Crucial Catalyst for Therapeutic Success. Cancers 15:23, pages 5694.
Crossref
Crossref
Irene Fiorilla, Simona Martinotti, Alberto Maria Todesco, Gregorio Bonsignore, Maria Cavaletto, Mauro Patrone, Elia Ranzato & Valentina Audrito. (2023) Chronic Inflammation, Oxidative Stress and Metabolic Plasticity: Three Players Driving the Pro-Tumorigenic Microenvironment in Malignant Mesothelioma. Cells 12:16, pages 2048.
Crossref
Crossref
Mary Helen Barcellos-Hoff & James L. Gulley. (2023) Molecular Pathways and Mechanisms of TGFβ in Cancer Therapy. Clinical Cancer Research 29:11, pages 2025-2033.
Crossref
Crossref
Shafat Ali, Muneeb U. Rehman, Ali Mohd Yatoo, Azher Arafah, Andleeb Khan, Summya Rashid, Sabhiya Majid, Aarif Ali & Md. Niamat Ali. (2023) TGF-β signaling pathway: Therapeutic targeting and potential for anti-cancer immunity. European Journal of Pharmacology 947, pages 175678.
Crossref
Crossref
Jenette Creaney, Ann-Marie Patch, Venkateswar Addala, Sophie A. Sneddon, Katia Nones, Ian M. Dick, Y. C. Gary Lee, Felicity Newell, Ebony J. Rouse, Marjan M. Naeini, Olga Kondrashova, Vanessa Lakis, Apostolos Nakas, David Waller, Annabel Sharkey, Pamela Mukhopadhyay, Stephen H. Kazakoff, Lambros T. Koufariotis, Aimee L. Davidson, Priya Ramarao-Milne, Oliver Holmes, Qinying Xu, Conrad Leonard, Scott Wood, Sean M. Grimmond, Raphael Bueno, Dean A. Fennell, John V. Pearson, Bruce W. Robinson & Nicola Waddell. (2022) Comprehensive genomic and tumour immune profiling reveals potential therapeutic targets in malignant pleural mesothelioma. Genome Medicine 14:1.
Crossref
Crossref
Santosh Kesari, Alberto Bessudo, Brian R Gastman, Anthony P Conley, Victoria M Villaflor, Lisle M Nabell, DeLisa Madere, Emma Chacon, Christina Spencer, Li Li, Christopher Larson, Tony Reid, Scott Caroen, Bryan Oronsky, Meaghan Stirn, Jeannie Williams & Minal A Barve. (2022) BETA PRIME: Phase I study of AdAPT-001 as monotherapy and combined with a checkpoint inhibitor in superficially accessible, treatment-refractory solid tumors. Future Oncology 18:29, pages 3245-3254.
Crossref
Crossref
Fabian A Mendoza & Sergio A Jimenez. (2022) Serine/threonine kinase inhibition as antifibrotic therapy: transforming growth factor-β and Rho kinase inhibitors. Rheumatology 61:4, pages 1354-1365.
Crossref
Crossref
Zai-Zai Cao, Yin-Jie Ao & Shui-Hong Zhou. (2021) The role of cancer stromal fibroblasts in mediating the effects of tobacco-induced cancer cell growth. Cancer Cell International 21:1.
Crossref
Crossref
Grégoire de Streel & Sophie Lucas. (2021) Targeting immunosuppression by TGF-β1 for cancer immunotherapy. Biochemical Pharmacology 192, pages 114697.
Crossref
Crossref
Huakan Zhao, Lei Wu, Guifang Yan, Yu Chen, Mingyue Zhou, Yongzhong Wu & Yongsheng Li. (2021) Inflammation and tumor progression: signaling pathways and targeted intervention. Signal Transduction and Targeted Therapy 6:1.
Crossref
Crossref
Ester Gonzalez-Sanchez, Javier Vaquero, Maite G. Férnandez-Barrena, Juan José Lasarte, Matías A. Avila, Pablo Sarobe, María Reig, Mariona Calvo & Isabel Fabregat. (2021) The TGF-β Pathway: A Pharmacological Target in Hepatocellular Carcinoma?. Cancers 13:13, pages 3248.
Crossref
Crossref
Emmanouil PapasavvasLivio AzzoniAmélie PagliuzzaMohamed Abdel-MohsenBrian N. RossMatthew FairBonnie J. HowellDaria J. HazudaNicolas ChomontQingsheng LiKaram MounzerJay R. KostmanPablo TebasLuis J. Montaner. (2021) Safety, Immune, and Antiviral Effects of Pegylated Interferon Alpha 2b Administration in Antiretroviral Therapy-Suppressed Individuals: Results of Pilot Clinical Trial. AIDS Research and Human Retroviruses 37:6, pages 433-443.
Crossref
Crossref
Lauren M. Kreps & Christina L. Addison. (2021) Targeting Intercellular Communication in the Bone Microenvironment to Prevent Disseminated Tumor Cell Escape from Dormancy and Bone Metastatic Tumor Growth. International Journal of Molecular Sciences 22:6, pages 2911.
Crossref
Crossref
Sijia Liu, Jiang Ren & Peter ten Dijke. (2021) Targeting TGFβ signal transduction for cancer therapy. Signal Transduction and Targeted Therapy 6:1.
Crossref
Crossref
Rik Derynck, Shannon J. Turley & Rosemary J. Akhurst. (2020) TGFβ biology in cancer progression and immunotherapy. Nature Reviews Clinical Oncology 18:1, pages 9-34.
Crossref
Crossref
Beverly A. Teicher. (2021) TGFβ-Directed Therapeutics: 2020. Pharmacology & Therapeutics 217, pages 107666.
Crossref
Crossref
D. Ciardiello, E. Elez, J. Tabernero & J. Seoane. (2020) Clinical development of therapies targeting TGFβ: current knowledge and future perspectives. Annals of Oncology 31:10, pages 1336-1349.
Crossref
Crossref
Yun Zhao, Sharif Rahmy, Zhongmin Liu, Chao Zhang & Xin Lu. (2020) Rational targeting of immunosuppressive neutrophils in cancer. Pharmacology & Therapeutics 212, pages 107556.
Crossref
Crossref
Monika Lodyga & Boris Hinz. (2020) TGF-β1 – A truly transforming growth factor in fibrosis and immunity. Seminars in Cell & Developmental Biology 101, pages 123-139.
Crossref
Crossref
Warisara Parichatikanond, Theerut Luangmonkong, Supachoke Mangmool & Hitoshi Kurose. (2020) Therapeutic Targets for the Treatment of Cardiac Fibrosis and Cancer: Focusing on TGF-β Signaling. Frontiers in Cardiovascular Medicine 7.
Crossref
Crossref
Yuhong Chen, Cuixia Di, Xuetian Zhang, Jing Wang, Fang Wang, Jun‐fang Yan, Caipeng Xu, Jinhua Zhang, Qianjing Zhang, Hongyan Li, Hongying Yang & Hong Zhang. (2019) Transforming growth factor β signaling pathway: A promising therapeutic target for cancer. Journal of Cellular Physiology 235:3, pages 1903-1914.
Crossref
Crossref
Paul Stockhammer, Till Ploenes, Dirk Theegarten, Martin Schuler, Sandra Maier, Clemens Aigner & Balazs Hegedus. (2020) Detection of TGF-β in pleural effusions for diagnosis and prognostic stratification of malignant pleural mesothelioma. Lung Cancer 139, pages 124-132.
Crossref
Crossref
Lucien P. Garo & Murugaiyan Gopal. 2020. Cancer Immunology. Cancer Immunology
205
233
.
Vincenzo Di Noia, Emanuele Vita, Miriam Ferrara, Antonia Strippoli, Michele Basso, Giovanni Schinzari, Alessandra Cassano, Emilio Bria, Carlo Barone & Ettore D’Argento. (2019) Malignant Pleural Mesothelioma: Is Tailoring the Second-Line Therapy Really “Raising the Bar?”. Current Treatment Options in Oncology 20:3.
Crossref
Crossref
Irina Zh. Zhubina, Irina O. Chikileva & Mikhail V. Kiselevskiy. 2019. Malignant Mesothelioma and Pseudomyxoma. Malignant Mesothelioma and Pseudomyxoma
101
120
.
Elisabeth Digifico, Cristina Belgiovine, Alberto Mantovani & Paola Allavena. 2019. Mesothelioma. Mesothelioma
69
84
.
Emmanouil Papasavvas, Steven M. Lada, Jocelin Joseph, Xiangfan Yin, Qin Liu, Livio Azzoni, Karam Mounzer, Jay R. Kostman, Douglas Richman & Luis J. Montaner. (2018) Analytical antiretroviral therapy interruption does not irreversibly change preinterruption levels of cellular HIV. AIDS 32:13, pages 1763-1772.
Crossref
Crossref
Philippe Lachapelle, Meina Li, Jo Douglass & Alastair Stewart. (2018) Safer approaches to therapeutic modulation of TGF-β signaling for respiratory disease. Pharmacology & Therapeutics 187, pages 98-113.
Crossref
Crossref
Carmen Belli, Dario Trapani, Giulia Viale, Paolo D'Amico, Bruno Achutti Duso, Paolo Della Vigna, Franco Orsi & Giuseppe Curigliano. (2018) Targeting the microenvironment in solid tumors. Cancer Treatment Reviews 65, pages 22-32.
Crossref
Crossref
Marie Viala, Marie Vinches, Marie Alexandre, Caroline Mollevi, Anna Durigova, Nadia Hayaoui, Krisztian Homicsko, Alice Cuenant, Céline Gongora, Luca Gianni & Diego Tosi. (2018) Strategies for clinical development of monoclonal antibodies beyond first-in-human trials: tested doses and rationale for dose selection. British Journal of Cancer 118:5, pages 679-697.
Crossref
Crossref
N. DeVito, M. A. Morse, B. Hanks & J. M. Clarke. 2018. Early Phase Cancer Immunotherapy. Early Phase Cancer Immunotherapy
219
241
.
Juan Du, Yu Yu, Jun Zhan & Hongquan Zhang. 2017. Translational Research in Breast Cancer. Translational Research in Breast Cancer
125
146
.
Yuen Yee Cheng, Casey M. Wright, Michaela B. Kirschner, Marissa Williams, Kadir H. Sarun, Vladimir Sytnyk, Iryna Leshchynska, J. James Edelman, Michael P. Vallely, Brian C. McCaughan, Sonja Klebe, Nico van Zandwijk, Ruby C. Y. Lin & Glen Reid. (2016) KCa1.1, a calcium-activated potassium channel subunit alpha 1, is targeted by miR-17-5p and modulates cell migration in malignant pleural mesothelioma. Molecular Cancer 15:1.
Crossref
Crossref
Paul Wheatley-Price, Quincy Chu, Maria Bonomi, Jean Seely, Ashish Gupta, Glenwood Goss, John Hilton, Ronald Feld, Christopher W. Lee, John R Goffin, Andrew Maksymiuk, Nevin Murray, Linda Hagerman & Penelope A. Bradbury. (2016) A Phase II Study of PF-03446962 in Patients with Advanced Malignant Pleural Mesothelioma. CCTG Trial IND.207. Journal of Thoracic Oncology 11:11, pages 2018-2021.
Crossref
Crossref
Raymond M. Wong. (2016) Modulating Immunosuppression in the Intrapleural Space of Malignant Pleural Mesothelioma and Predictive Biomarkers to Guide Treatment Decisions. Journal of Thoracic Oncology 11:10, pages 1602-1603.
Crossref
Crossref
Jeffry S. Nyman, Alyssa R. Merkel, Sasidhar Uppuganti, Bijaya Nayak, Barbara Rowland, Alexander J. Makowski, Babatunde O. Oyajobi & Julie A. Sterling. (2016) Combined treatment with a transforming growth factor beta inhibitor (1D11) and bortezomib improves bone architecture in a mouse model of myeloma-induced bone disease. Bone 91, pages 81-91.
Crossref
Crossref
Jason S. Rockel & Mohit Kapoor. (2016) Autophagy: controlling cell fate in rheumatic diseases. Nature Reviews Rheumatology 12:9, pages 517-531.
Crossref
Crossref
Kristian Hargadon. (2016) Dysregulation of TGFβ1 Activity in Cancer and Its Influence on the Quality of Anti-Tumor Immunity. Journal of Clinical Medicine 5:9, pages 76.
Crossref
Crossref
Daniel H. Sterman, Evan Alley, James P. Stevenson, Joseph Friedberg, Susan Metzger, Adri Recio, Edmund K. Moon, Andrew R. Haas, Anil Vachani, Sharyn I. Katz, Jing Sun, Daniel F. Heitjan, Wei-Ting Hwang, Leslie Litzky, Jennifer H. Yearley, Kay See Tan, Emmanouil Papasavvas, Paul Kennedy, Luis J. Montaner, Keith A. Cengel, Charles B. SimoneIIII, Melissa Culligan, Corey J. Langer & Steven M. Albelda. (2016) Pilot and Feasibility Trial Evaluating Immuno-Gene Therapy of Malignant Mesothelioma Using Intrapleural Delivery of Adenovirus-IFNα Combined with Chemotherapy. Clinical Cancer Research 22:15, pages 3791-3800.
Crossref
Crossref
Andrew W. Holle, Jennifer L. Young & Joachim P. Spatz. (2016) In vitro cancer cell–ECM interactions inform in vivo cancer treatment. Advanced Drug Delivery Reviews 97, pages 270-279.
Crossref
Crossref
Vivek Nagaraja, Christopher P. Denton & Dinesh Khanna. (2015) Old medications and new targeted therapies in systemic sclerosis. Rheumatology 54:11, pages 1944-1953.
Crossref
Crossref
Martha W. den Hollander, Frederike Bensch, Andor W.J.M. Glaudemans, Thijs H. Oude Munnink, Roelien H. Enting, Wilfred F.A. den Dunnen, Mart A.A.M. Heesters, Frank A.E. Kruyt, Marjolijn N. Lub-de Hooge, Jan Cees de Groot, Joseph Pearlberg, Jourik A. Gietema, Elisabeth G.E. de Vries & Annemiek M.E. Walenkamp. (2015)
TGF-β Antibody Uptake in Recurrent High-Grade Glioma Imaged with
89
Zr-Fresolimumab PET
. Journal of Nuclear Medicine 56:9, pages 1310-1314.
Crossref
Crossref
R.A. Stahel, W. Weder, E. Felley-Bosco, U. Petrausch, A. Curioni-Fontecedro, I. Schmitt-Opitz & S. Peters. (2015) Searching for targets for the systemic therapy of mesothelioma. Annals of Oncology 26:8, pages 1649-1660.
Crossref
Crossref
Lisa M. Rice, Cristina M. Padilla, Sarah R. McLaughlin, Allison Mathes, Jessica Ziemek, Salma Goummih, Sashidhar Nakerakanti, Michael York, Giuseppina Farina, Michael L. Whitfield, Robert F. Spiera, Romy B. Christmann, Jessica K. Gordon, Janice Weinberg, Robert W. Simms & Robert Lafyatis. (2015) Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients. Journal of Clinical Investigation 125:7, pages 2795-2807.
Crossref
Crossref
J. Remon, N. Reguart, J. Corral & P. Lianes. (2015) Malignant pleural mesothelioma: New hope in the horizon with novel therapeutic strategies. Cancer Treatment Reviews 41:1, pages 27-34.
Crossref
Crossref
Aaron Moulin, Magali Mathieu, Catherine Lawrence, Russell Bigelow, Mark Levine, Christine Hamel, Jean-Piere Marquette, Josiane Le Parc, Christophe Loux, Paul Ferrari, Cecile Capdevila, Jacques Dumas, Bruno Dumas, Alexey Rak, Julie Bird, Huawei Qiu, Clark Q. Pan, Tim Edmunds & Ronnie R. Wei. (2014) Structures of a pan-specific antagonist antibody complexed to different isoforms of TGFβ reveal structural plasticity of antibody-antigen interactions. Protein Science 23:12, pages 1698-1707.
Crossref
Crossref
Hans Anton Schlößer, Sebastian Theurich, Alexander Shimabukuro-Vornhagen, Udo Holtick, Dirk Ludger Stippel & Michael von Bergwelt-Baildon. (2014) Overcoming tumor-mediated immunosuppression. Immunotherapy 6:9, pages 973-988.
Crossref
Crossref
Jing Ai & James P. Stevenson. (2014) Current Issues in Malignant Pleural Mesothelioma Evaluation and Management. The Oncologist 19:9, pages 975-984.
Crossref
Crossref
A. Scherpereel & X. Dhalluin. (2014) Mésothéliome pleural malin : la chimiothérapie est-elle la seule option thérapeutique ?. Revue des Maladies Respiratoires Actualités 6:4, pages 530-539.
Crossref
Crossref
Patrick C. Gedeon, Katherine A. Riccione, Peter E. Fecci & John H. Sampson. (2014) Antibody-Based Immunotherapy for Malignant Glioma. Seminars in Oncology 41:4, pages 496-510.
Crossref
Crossref
Sen Zhang, Wu-Yi Sun, Jing-Jing Wu & Wei Wei. (2014) TGF-? signaling pathway as a pharmacological target in liver diseases. Pharmacological Research 85, pages 15-22.
Crossref
Crossref
Anne-Sophie Chretien, Aude Le Roy, Norbert Vey, Thomas Prebet, Didier Blaise, Cyril Fauriat & Daniel Olive. (2014) Cancer-Induced Alterations of NK-Mediated Target Recognition: Current and Investigational Pharmacological Strategies Aiming at Restoring NK-Mediated Anti-Tumor Activity. Frontiers in Immunology 5.
Crossref
Crossref